\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Associated Publications}{}% 5
\BOOKMARK [0][-]{chapter*.7}{Contents}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Figures}{}% 7
\BOOKMARK [0][-]{chapter*.10}{List of Tables}{}% 8
\BOOKMARK [0][-]{chapter*.11}{Abbreviations}{}% 9
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 10
\BOOKMARK [1][-]{section.1.1}{Psoriasis and psoriatic arthritis}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.1.1}{Epidemiology and global impact}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.2}{Psoriasis and inflammatory dermatoses}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.3}{PsA and spondyloarthropaties}{section.1.1}% 14
\BOOKMARK [1][-]{section.1.2}{Pathophysiology of psoriasis and psoriatic arthritis}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.2.1}{Clinical presentation and diagnosis}{section.1.2}% 16
\BOOKMARK [2][-]{subsection.1.2.2}{Aetiology of psoriasis and PsA}{section.1.2}% 17
\BOOKMARK [2][-]{subsection.1.2.3}{Cell types involved in psoriasis and PsA pathogenesis}{section.1.2}% 18
\BOOKMARK [2][-]{subsection.1.2.4}{Therapeutic intervention and prognosis}{section.1.2}% 19
\BOOKMARK [1][-]{section.1.3}{Genetics of psoriasis and psoriatic arthritis}{chapter.1}% 20
\BOOKMARK [2][-]{subsection.1.3.1}{Heritability}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.2}{Non-GWAS and linkage studies}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.3}{Genome-wide association studies}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.4}{Relevance of non-coding versus coding variants in disease susceptibility}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.5}{The role of GWAS studies in highlighting immune-relevant cell types and pathways}{section.1.3}% 25
\BOOKMARK [2][-]{subsection.1.3.6}{Limitations and future of GWAS studies}{section.1.3}% 26
\BOOKMARK [1][-]{section.1.4}{Functional interpretation of genome-wide association studies in complex diseases}{chapter.1}% 27
\BOOKMARK [2][-]{subsection.1.4.1}{Overcoming the limitations of GWAS: post-GWAS studies}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.2}{The use of fine-mapping to prioritise causal variants}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.3}{Understanding the epigenetic landscape in complex diseases}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.4}{The chromatin landscape}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.5}{Transcriptional profiles in disease}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.6}{Transcriptional regulation in complex diseases}{section.1.4}% 33
\BOOKMARK [2][-]{subsection.1.4.7}{Integration and interpretation of data}{section.1.4}% 34
\BOOKMARK [2][-]{subsection.1.4.8}{Approaches to establish disease mechanisms and causality of genetic variant}{section.1.4}% 35
\BOOKMARK [0][-]{chapter.2}{Material and Methods}{}% 36
\BOOKMARK [1][-]{section.2.1}{Ethical approval and recruitment of study participants}{chapter.2}% 37
\BOOKMARK [2][-]{subsection.2.1.1}{Psoriasis patient recruitment}{section.2.1}% 38
\BOOKMARK [2][-]{subsection.2.1.2}{PsA patient recruitment}{section.2.1}% 39
\BOOKMARK [2][-]{subsection.2.1.3}{Healthy volunteer recruitment}{section.2.1}% 40
\BOOKMARK [1][-]{section.2.2}{Sample processing}{chapter.2}% 41
\BOOKMARK [2][-]{subsection.2.2.1}{PBMC and synovial fluid cells isolation}{section.2.2}% 42
\BOOKMARK [2][-]{subsection.2.2.2}{Primary cell isolation using magnetic-activated cell sorting}{section.2.2}% 43
\BOOKMARK [2][-]{subsection.2.2.3}{Primary cell isolation using fluorescence-activated cell sorting}{section.2.2}% 44
\BOOKMARK [2][-]{subsection.2.2.4}{Skin biopsies processing and adherent assay}{section.2.2}% 45
\BOOKMARK [1][-]{section.2.3}{Experimental protocols}{chapter.2}% 46
\BOOKMARK [2][-]{subsection.2.3.1}{Cryopreservation and cell culture}{section.2.3}% 47
\BOOKMARK [2][-]{subsection.2.3.2}{ATAC-seq, Fast-ATAC and Omni-ATAC}{section.2.3}% 48
\BOOKMARK [2][-]{subsection.2.3.3}{Chromatin Immunoprecipitation with sequencing library preparation by Tn5 transposase}{section.2.3}% 49
\BOOKMARK [2][-]{subsection.2.3.4}{RNA extraction and RNA-seq}{section.2.3}% 50
\BOOKMARK [2][-]{subsection.2.3.5}{Single-cell analysis of the V\(D\)J T cell receptor repertoire}{section.2.3}% 51
\BOOKMARK [2][-]{subsection.2.3.6}{DNA extraction and SNP genotyping}{section.2.3}% 52
\BOOKMARK [2][-]{subsection.2.3.7}{Mass cytometry analysis}{section.2.3}% 53
\BOOKMARK [1][-]{section.2.4}{Computational and statistical analysis}{chapter.2}% 54
\BOOKMARK [2][-]{subsection.2.4.1}{ATAC-seq data analysis}{section.2.4}% 55
\BOOKMARK [2][-]{subsection.2.4.2}{ChIPm data analysis}{section.2.4}% 56
\BOOKMARK [2][-]{subsection.2.4.3}{RNA-seq data analysis}{section.2.4}% 57
\BOOKMARK [2][-]{subsection.2.4.4}{Genomic region annotation, pathway enrichment analysis and visualisation}{section.2.4}% 58
\BOOKMARK [2][-]{subsection.2.4.5}{Enrichment analysis for genomic annotation features}{section.2.4}% 59
\BOOKMARK [2][-]{subsection.2.4.6}{Statistical fine-mapping}{section.2.4}% 60
\BOOKMARK [0][-]{chapter.3}{Establishment of laboratory methods and analytical tools to assess genome-wide chromatin accessibility in clinical samples}{}% 61
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 62
\BOOKMARK [1][-]{section.3.2}{Results}{chapter.3}% 63
\BOOKMARK [2][-]{subsection.3.2.1}{Establishment of an ATAC-seq data analysis pipeline based on current knowledge}{section.3.2}% 64
\BOOKMARK [2][-]{subsection.3.2.2}{Assessment of ATAC-seq transposition times and comparison with FAST-ATAC protocol in relevant cell types}{section.3.2}% 65
\BOOKMARK [2][-]{subsection.3.2.3}{Limitations of ATAC-seq and FAST-ATAC to assess chromatin accessibility in KC}{section.3.2}% 66
\BOOKMARK [2][-]{subsection.3.2.4}{Discussion}{section.3.2}% 67
\BOOKMARK [0][-]{chapter.4}{Cross-tissue comparison of chromatin accessibility, gene expression signature and immunophenotypes in psoriatic arthritis}{}% 68
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 69
\BOOKMARK [1][-]{section.4.2}{Results}{chapter.4}% 70
\BOOKMARK [2][-]{subsection.4.2.1}{PsA patients cohort description and datasets}{section.4.2}% 71
\BOOKMARK [2][-]{subsection.4.2.2}{Differences in the chromatin accessibility landscape between circulating and SF immune cells}{section.4.2}% 72
\BOOKMARK [2][-]{subsection.4.2.3}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.4.2}% 73
\BOOKMARK [1][-]{section.4.3}{Discussion}{chapter.4}% 74
\BOOKMARK [0][-]{section.4.3}{Appendices}{}% 75
\BOOKMARK [0][-]{appendix.A}{Establishment of methods to assess genome-wide chromatin accessibility}{}% 76
\BOOKMARK [0][-]{appendix*.70}{Bibliography}{}% 77
